Autres langues Chemomab Therapeutics Ltd.

Actions

CMMB

US16385C1045

Temps Différé Nasdaq Autres places de cotation 17:55:07 27/06/2024			Varia. 5j.	Varia. 1 janv.
1 ^USD	0,00 %		+7,53 %	+96,08 %

18/06	Chemomab Therapeutics Ltd. annonce de nouvelles publications renforçant le potentiel clinique de son anticorps neutralisant la protéine CCL24, le CM-101, dans la cholangite sclérosante primaire.	CI
06/05	CHEMOMAB THERAPEUTICS LTD. : Oppenheimer réajuste son opinion à la hausse	ZM

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	18/06
Chemomab Therapeutics Ltd. Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	18/06
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference	06/06
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference	06/06
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences	20/05
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences	17/05
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule	08/05
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule	08/05
Chemomab Therapeutics : Notice and Proxy Statement with respect to the Company’s annual general meeting of the shareholders (the “Meeting”) to be held on June 10, 2024, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting - Form 6-K	03/05
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference	02/05
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	24/04
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	24/04
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis	18/04
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	02/04
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	02/04
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	25/03
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	25/03
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update	08/03
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Chemomab Therapeutics Ltd.

Actions

CMMB

US16385C1045

Autres langues

Filtres